FIELD: pharmacology.
SUBSTANCE: invention describes a liquid dosage form of risperidone in the form of an oral solution comprising an active substance and a combination of excipients having the following composition in mg/ml: Risperidone 1; Tartaric acid 7.5; Sodium benzoate 2.36; Sodium hydroxide to pH 3.0±0.2; Purified water to 1 ml.
EFFECT: invention provides a liquid dosage form that is stable in production and long-term storage, and involves a more technological method of production, consisting in the absence of the need to heat the aqueous solution by dissolving an antimicrobial preservative to be incorporated into the liquid dosage form.
2 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CARRYING OUT COMBINED REDUCTION OF SCHIZO-AFFECTIVE SYNDROMES OF PSYCHOTIC AND SUBPSYCHOTIC LEVEL IN DAY CARE HOSPITAL | 2003 |
|
RU2249456C1 |
| LIQUID DOSAGE FORM FOR ORAL ADMINISTRATION, HAVING NOOTROPIC ACTIVITY | 2018 |
|
RU2703293C1 |
| STABLE PHARMACEUTICAL COMPOSITION LAMIVUDINE | 2015 |
|
RU2587782C1 |
| DERIVATIVES OF 7-FLUORO-8-CHLORO-5H-DIBENZO [B, E] [1, 4] DIAZEPINE AND THEIR APPLICATION | 2014 |
|
RU2610169C2 |
| AQUEOUS RISPERIDONE COMPOSITIONS | 1995 |
|
RU2161965C2 |
| LIQUID DOSAGE FORM OF FENSPIRIDE AND PRODUCTION METHOD THEREOF | 2015 |
|
RU2607965C1 |
| MIXTURE CONTAINING CARBAMATE COMPOUND FOR PREVENTION, RELIEF OR TREATMENT OF SCHIZOPHRENIA | 2018 |
|
RU2772465C2 |
| THERAPEUTIC AGENTS | 2008 |
|
RU2468025C2 |
| ONDANSETRON-CONTAINING COMPOSITIONS FOR ORAL ADMINISTRATION | 1995 |
|
RU2145853C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FUNCTIONAL MENTAL DISORDERS | 2016 |
|
RU2667954C2 |
